OS Therapies OSTX 深 滬
等待開盤 08-21 09:30:00 美东时间
1.58
+0.120
+8.22%
華盛通- 最 高1.58
- 今 開1.50
- 成交量 36.96万股
- 最 低 1.45
- 昨 收 1.46
- 總市值 7287.88万
- 52周最高 2.36
- 市盈率 靜 --
- 換手率 0.80%
- 52周最低 1.15
- 委 比 50.00%
- 總股本 4612.58万
- 歷史最高 7.00
- 量 比 0.70
- 振 幅 8.90%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OS Therapies Announces Convertible Note Financing and Warrants
OS Therapies Incorporated ( ($OSTX) ) has provided an update. On August 10, 202...
08-13 05:19
OS Therapies Settles Leonite Debt, Issues Bridge Financing
An update from OS Therapies Incorporated ( ($OSTX) ) is now available. On June ...
08-07 04:46
OS Therapies Ends At-The-Market Equity Sales Program
OS Therapies Incorporated ( ($OSTX) ) just unveiled an announcement. On July 23...
07-30 05:29
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
OS Therapies Terminates At Market Issuance Sales Agreement On July 23; Co. Announces Termination Of Sales Agreement Effective July 28
07-30 05:15
美股大行评级 | 潜在涨幅246.92%！HC Wainwright & Co.上调Rockwell Medical(RMTI)目标价至20美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Rockwell Medical"买入"评级，目标价从2美元升至20美元；Canaccord Genuity：维持创力"买入"评级，目标价从10.5美元升至11美元
07-10 17:36
OS Therapies Accepts New FDA Meeting Request For Review Of Pharmacodynamic Response Biomarker Data
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to re...
07-08 21:08
OS Therapies Requests FDA Type B Meeting To Review Its 2.5-Year OST-HER2 Overall Survival Data And To Confirm Alignment That 3-year Overall Survival Data Is A Clinical Endpoint
OS Therapies, Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provided regulatory update on the Company's interactions with the U.S. Food and Drug Administration (FDA) in its pursuit of a Biologics License Application ...
06-30 19:45
OS疗法公司称新骨癌数据为监管申报提供有力支持
OS疗法公司（NYSE:OSTX）股价周二盘前上涨，因其宣布OST - HER2的2b期试验在2.5年节点取得有统计学意义的总体生存结果。 试验显示，肺转移骨肉...
06-02 19:29
OS Therapies Announces Its Phase 2b Trial Of OST-HER2 In The Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma Achieved Statistically Significant Benefit For OST-HER2 Treated Patients In Overall Survival At The 2.5-Year Mark
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated clinical efficacy data
06-02 18:07
